![Entering a New Era of Patient-Reported Outcomes in Inflammatory Bowel Disease: Past, Present, and Future - European Medical Journal Entering a New Era of Patient-Reported Outcomes in Inflammatory Bowel Disease: Past, Present, and Future - European Medical Journal](https://emj.emg-health.com/wp-content/uploads/sites/2/2018/08/EMJ-Gastroenterol.-2018-Suppl-2-Takeda.jpg)
Entering a New Era of Patient-Reported Outcomes in Inflammatory Bowel Disease: Past, Present, and Future - European Medical Journal
![PDF) ECCO-ESGAR guideline for diagnostic assessment in IBD part 1: initial diagnosis, monitoring of known IBD, detection of complications PDF) ECCO-ESGAR guideline for diagnostic assessment in IBD part 1: initial diagnosis, monitoring of known IBD, detection of complications](https://i1.rgstatic.net/publication/339011349_ECCO-ESGAR_guideline_for_diagnostic_assessment_in_IBD_part_1_initial_diagnosis_monitoring_of_known_IBD_detection_of_complications/links/5f8990c792851c14bccc3896/largepreview.png)
PDF) ECCO-ESGAR guideline for diagnostic assessment in IBD part 1: initial diagnosis, monitoring of known IBD, detection of complications
![British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults | Gut British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults | Gut](https://gut.bmj.com/content/gutjnl/68/Suppl_3/s1/F5.large.jpg)
British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults | Gut
![Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease | SpringerLink Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs10620-019-06036-0/MediaObjects/10620_2019_6036_Fig1_HTML.png)
Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease | SpringerLink
![Phase 2, Randomized, Placebo-Controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andecaliximab, in Patients With Moderately to Severely Active Crohn's Disease | Journal of Crohn's and Colitis | Oxford Academic Phase 2, Randomized, Placebo-Controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andecaliximab, in Patients With Moderately to Severely Active Crohn's Disease | Journal of Crohn's and Colitis | Oxford Academic](https://oup-silverchair-cdn-com.eres.qnl.qa/oup/backfile/Content_public/Journal/ecco-jcc/Issue/12/9/1/m_cover.png?Expires=1625495759&Signature=dr~V0dRZv8CfmgrK-d4x4P7acKvlcNlKBm3VeRtTfCdd6lQkZiem4lQvqMsZhkLwHxmIOdAidOfXpuDHCn5SkrddDj8GcQPRReGSQRUwTGXWqHEYlV6VrqeHdMBmmF-eFRDrV3oBEEry2U4eDrTdCH34Sr7h7eAaWnYngVJraWDbUR6sOVoLJDiPtZqaQYQz7Elh44RPDXozt2QIxOg6g4ao~VgLvqzJADp2Teadt7fR1p-KaWGuvz-A3eiXxwZkz3ixJ7fP8CqYsW2WAhbmHJRYJpWD8fgQQN18UvH-jk6lwwmn6~tsFjxq75OcPpjIHkVsoQmw~4Y56Wt1VxjFzA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Phase 2, Randomized, Placebo-Controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andecaliximab, in Patients With Moderately to Severely Active Crohn's Disease | Journal of Crohn's and Colitis | Oxford Academic
![Pfizer Inc. on Twitter: "As part of our commitment to delivering the highest value of care to patients, we are investing significant resources to develop and deliver high-quality #biosimilars #ECCO2018… https://t.co/8UpqhCS3BZ" Pfizer Inc. on Twitter: "As part of our commitment to delivering the highest value of care to patients, we are investing significant resources to develop and deliver high-quality #biosimilars #ECCO2018… https://t.co/8UpqhCS3BZ"](https://pbs.twimg.com/media/DWK2MEkWAAA1EHi.jpg)
Pfizer Inc. on Twitter: "As part of our commitment to delivering the highest value of care to patients, we are investing significant resources to develop and deliver high-quality #biosimilars #ECCO2018… https://t.co/8UpqhCS3BZ"
![Patient Centricity in IBD Treatment: An Interview with Dr Corey Siegel at the 13th Congress of ECCO - European Medical Group Patient Centricity in IBD Treatment: An Interview with Dr Corey Siegel at the 13th Congress of ECCO - European Medical Group](https://www.emg-health.com/wp-content/uploads/2018/04/Patient-Centricity-in-IBD-Treatment-An-Interview-with-Dr-Corey-Siegel-at-the-13th-Congress-of-ECCO.jpg)
Patient Centricity in IBD Treatment: An Interview with Dr Corey Siegel at the 13th Congress of ECCO - European Medical Group
![British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults | Gut British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults | Gut](https://gut.bmj.com/content/gutjnl/68/Suppl_3/s1/F2.large.jpg)